Open AccessGenetic Polymorphism of GABRG2 rs211037 is Associated with Drug Response and Adverse Drug Reactions to Valproic Acid in Chinese Southern Children with Epilepsy
Author(s) -
Jieluan Lu,
Han-Bing Xia,
Wenzhou Li,
Xianhuan Shen,
Huijuan Guo,
Jianping Zhang,
Xiaomei Fan
Publication year - 2021
Publication title -
pharmacogenomics and personalized medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 28
ISSN - 1178-7066
DOI - 10.2147/pgpm.s329594
Subject(s) - valproic acid , medicine , epilepsy , childhood absence epilepsy , genotype , adverse effect , pharmacology , pharmacogenetics , bioinformatics , oncology , genetics , psychiatry , gene , biology
Valproic acid (VPA) is recommended as a first-line treatment for children with epilepsy. GABRG2 polymorphism is found to be associated with epilepsy susceptibility and therapeutic response of anti-seizure medications (ASM); however, the role of GABRG2 in VPA treatment still remains unknown.